Talk:GLP-1 receptor agonist

Requested move 5 November 2023

The following is a closed discussion of a requested move. Please do not modify it. Subsequent comments should be made in a new section on the talk page. Editors desiring to contest the closing decision should consider a move review after discussing it on the closer's talk page. No further edits should be made to this discussion.

The result of the move request was: Moved (closed by non-admin page mover) BegbertBiggs (talk) 15:15, 12 November 2023 (UTC)

---

Glucagon-like peptide-1 receptor agonist → GLP-1 receptor agonist – The majority of scholarly sources don't seem to be spelling out the name, per Google Scholar results since 2019:

• GLP-1 agonist: 4,000
• GLP-1 receptor agonist: 10,600
• "Glucagon-like peptide-1 receptor agonist" 9700
• "Glucagon-like peptide-1 agonist": 900

Thus, I think it meets WP:ACROTITLE for using an acronym in the title, and I also think that GLP-1 is more recognizable to our readership than the spelled out name. I would also support "GLP-1 agonist" if that's what the consensus goes for, as this term is used in many sources aimed at a popular audience (see Google search or news results). (t · c) buidhe 04:30, 5 November 2023 (UTC)

Support - following Wikipedia:ACROTITLE . But just a comment that related pages are not moved yet. See Glucagon-like peptide-1 and Glucagon-like peptide-1 receptor Hongsy (talk) 02:41, 9 November 2023 (UTC)

It's not necessarily the case that they need or should be the same, after all we have Central Intelligence Agency but CIA controversies. I think the other articles need evaluating on their own merits especially since they are of more scientific /less popular interest than this article. (t · c) buidhe 02:52, 9 November 2023 (UTC)

The discussion above is closed. Please do not modify it. Subsequent comments should be made on the appropriate discussion page. No further edits should be made to this discussion.